Overcoming endocrine resistance in metastatic hormone receptor-positive breast cancer

Endocrine therapy has historically formed the basis of treatment of metastatic hormone receptor-positive breast cancer. The development of endocrine resistance has led to the development of newer endocrine drug combinations. Use of the CDK4/6 inhibitors has significantly improved progression-free su...

Full description

Saved in:
Bibliographic Details
Published in:Journal of hematology and oncology 2018-06, Vol.11 (1), p.80-80, Article 80
Main Authors: D'Souza, Anishka, Spicer, Darcy, Lu, Janice
Format: Article
Language:English
Subjects:
Breast cancer
Care and treatment
Cell cycle
Cell division
Complications and side effects
Cyclin-dependent kinase 4
Development and progression
Dosage and administration
Drug therapy
Endocrine therapy
Genetic aspects
Hematology
Kinases
Metabolism
Metabolites
Metastases
Metastasis
Mutation
Oncology
Phosphorylation
Quality of life
Review
Tamoxifen
TOR protein
Tumors
Womens health
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Endocrine therapy has historically formed the basis of treatment of metastatic hormone receptor-positive breast cancer. The development of endocrine resistance has led to the development of newer endocrine drug combinations. Use of the CDK4/6 inhibitors has significantly improved progression-free survival in this group of patients. There are multiple studies of the use of P13K inhibitors and mTOR inhibitors for use as subsequent lines of therapy, particularly for endocrine resistance. The optimal sequencing of therapy should be based on medical comorbidities, prior adjuvant therapies, quality of life, side-effect profile, and disease-free interval.
ISSN:1756-8722
1756-8722
DOI:10.1186/s13045-018-0620-6